<p>丹纳赫公司 (DHR) 下跌了 3.55%。医疗服务与设备行业下跌了 1.46%。该公司的表现不及行业平均水平。该行业成交量前 3 名股票：联合健康集团 (UNH) 下跌 2.40%；Hims &amp; Hers Health Inc (HIMS) 下跌 3.27%；斯特莱克公司 (SYK) 下跌 1.76%。</p>
<p><img src="https://imageproxy.pbkrs.com/https://resource.tradingkey.com/ai/wkrepot/9ead6b2b-cc4d-4422-9006-45fe73efc01a_1773339313.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://resource.tradingkey.com/ai/wkrepot/9ead6b2b-cc4d-4422-9006-45fe73efc01a_1773339313.png"/></p>
<h2>今天是什么原因导致丹纳赫公司 (DHR) 的股价下跌？</h2>
<p>丹纳赫公司 (DHR) 在盘中交易中经历了显著下跌，这可能受到公司特定发展和更广泛行业动态的多重因素影响。尽管当天没有报告单一的灾难性事件，但对公司前景的重新评估和当前市场情绪似乎是影响因素。</p>
<p>丹纳赫所处的更广泛的医疗和生命科学行业正在应对复杂的环境。尽管技术进步和人工智能的日益采用提高了效率，但该行业仍面临持续的挑战，包括不断上升的财务压力、劳动力短缺、供应成本上升以及不断变化的监管框架。地缘政治因素和供应链韧性也在积极塑造该行业的制造策略。这些总体逆风可能导致投资者对即使是处于良好位置的公司采取更谨慎的态度。</p>
<p>从公司特定的角度来看，市场可能正在消化丹纳赫以 99 亿美元收购麦斯莫医疗 (Masimo Corp.) 的影响，该交易于 2 月宣布。尽管预计该交易将在长期内对每股收益产生积极影响，并旨在扩大丹纳赫的诊断产品组合，但它也大幅增加了公司的净债务负担。关于整合过程、潜在的监管延误或预计的成本协同是否会完全实现的担忧可能正在影响投资者情绪。</p>
<p>此外，丹纳赫在 1 月底提供的 2026 年全年指导被一些分析师视为保守。公司预计非 GAAP 核心收入增长在 3% 到 6% 之间，调整后的稀释每股收益在 8.35 美元到 8.50 美元之间。尽管机构投资者的活动表现不一，有些在近期增加了持股，但由于估值的紧张感与此指导相结合，可能导致一些市场参与者重新评估他们的持仓。分析师情绪总体上是积极的，达成了 “适度买入” 的共识，但包括之前的下调，指出了溢价估值和对增长轨迹的担忧，特别是关于中国的复苏和持续的诊断增长。</p>
<h2>丹纳赫公司 (DHR) 的技术分析</h2>
<p>从技术上看，丹纳赫公司 (DHR) 的 MACD (12,26,9) 值为 [-5.82]，显示出卖出信号。RSI 为 29.09，表明卖出状态，Williams %R 为 -90.95，表明超卖状态。请密切关注。</p>
<h2>丹纳赫公司 (DHR) 的基本面分析</h2>
<p>丹纳赫公司 (DHR) 处于医疗服务与设备行业。其最新年收入为 245.7 亿美元，在行业中排名第 7。净利润为 36.1 亿美元，在行业中排名第 4。公司简介</p>
<p>在过去一个月中，多位分析师将该公司评级为买入，平均目标价为 263.31 美元，最高价为 310.00 美元，最低价为 220.00 美元。</p>
<h2>关于丹纳赫公司 (DHR) 的更多细节</h2>
<p>公司特定风险：</p>
<ul>
<li>最近以 99 亿美元的溢价收购麦斯莫医疗导致财务杠杆上升，使丹纳赫的债务与股本比率增加至约 3.2 倍。</li>
<li>市场对麦斯莫收购的价值创造潜力持怀疑态度，同时对丹纳赫在最近几年表现滞后和失去动力的担忧依然存在。</li>
<li>丹纳赫在其关键市场领域面临日益激烈的竞争环境，最近主要竞争对手安捷伦科技 (Agilent Technologies) 的强劲表现和提高的收入指导便是明证。</li>
</ul>
<p>了解更多</p>

标普健康医疗设备 ETF - SPDR

麦斯莫医疗

美国医药设备 ETF - iShares

丹纳赫

<p>丹纳赫公司 (Danaher Corp, DHR) 的股价下跌了 3.55%，受到公司特定发展和更广泛行业挑战的影响。医疗保健行业面临财务压力、劳动力短缺和成本上升。对丹纳赫以 99 亿美元收购麦斯莫医疗 (Masimo Corp) 的担忧增加了债务，同时对 2026 年的保守增长指引也影响了投资者情绪。技术指标显示出卖出信号，而分析师则维持 “适度买入” 的共识，机构活动呈现混合状态。丹纳赫的高财务杠杆和来自竞争对手如安捷伦科技 (Agilent Technologies) 的竞争压力加剧了市场的怀疑情绪</p>

<p>Danaher Corp (DHR) moved down by 3.55%. The Healthcare Services &amp; Equipment sector is down by 1.46%. The company underperformed the industry. Top 3 stocks by turnover in the sector: Unitedhealth Group Inc (UNH) down 2.40%; Hims &amp; Hers Health Inc (HIMS) down 3.27%; Stryker Corp (SYK) down 1.76%.</p>
<div class="lb-trans"><p>丹纳赫公司 (DHR) 下跌了 3.55%。医疗服务与设备行业下跌了 1.46%。该公司的表现不及行业平均水平。该行业成交量前 3 名股票：联合健康集团 (UNH) 下跌 2.40%；Hims &amp; Hers Health Inc (HIMS) 下跌 3.27%；斯特莱克公司 (SYK) 下跌 1.76%。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://resource.tradingkey.com/ai/wkrepot/9ead6b2b-cc4d-4422-9006-45fe73efc01a_1773339313.png" alt="" original-src="https://resource.tradingkey.com/ai/wkrepot/9ead6b2b-cc4d-4422-9006-45fe73efc01a_1773339313.png"/></p>
<h2>What is driving Danaher Corp (DHR)’s stock price down today?</h2>
<div class="lb-trans"><h2>今天是什么原因导致丹纳赫公司 (DHR) 的股价下跌？</h2>
</div><p>Danaher Corporation (DHR) experienced a notable decline during intraday trading, likely influenced by a confluence of factors stemming from both specific company developments and broader industry dynamics. While no single catastrophic event was reported on the day, a re-evaluation of the company's outlook and prevailing market sentiment appear to be contributing elements.</p>
<div class="lb-trans"><p>丹纳赫公司 (DHR) 在盘中交易中经历了显著下跌，这可能受到公司特定发展和更广泛行业动态的多重因素影响。尽管当天没有报告单一的灾难性事件，但对公司前景的重新评估和当前市场情绪似乎是影响因素。</p>
</div><p>The broader healthcare and life sciences sectors, in which Danaher operates, are navigating a complex landscape. Despite technological advancements and increasing adoption of AI for efficiency, the industry faces ongoing challenges including escalating financial pressures, workforce shortages, rising supply costs, and evolving regulatory frameworks. Geopolitical considerations and supply chain resilience are also actively shaping manufacturing strategies within the sector. Such overarching headwinds can contribute to a more cautious investor stance toward even well-positioned companies.</p>
<div class="lb-trans"><p>丹纳赫所处的更广泛的医疗和生命科学行业正在应对复杂的环境。尽管技术进步和人工智能的日益采用提高了效率，但该行业仍面临持续的挑战，包括不断上升的财务压力、劳动力短缺、供应成本上升以及不断变化的监管框架。地缘政治因素和供应链韧性也在积极塑造该行业的制造策略。这些总体逆风可能导致投资者对即使是处于良好位置的公司采取更谨慎的态度。</p>
</div><p>From a company-specific perspective, the market may be digesting the implications of Danaher's significant $9.9 billion acquisition of Masimo Corp., announced in February. While this deal is anticipated to be accretive to earnings per share in the long term and aims to expand Danaher's diagnostics portfolio, it also substantially increases the company's net debt load. Concerns regarding the integration process, potential regulatory delays, or whether the projected cost synergies will fully materialize could be weighing on investor sentiment.</p>
<div class="lb-trans"><p>从公司特定的角度来看，市场可能正在消化丹纳赫以 99 亿美元收购麦斯莫医疗 (Masimo Corp.) 的影响，该交易于 2 月宣布。尽管预计该交易将在长期内对每股收益产生积极影响，并旨在扩大丹纳赫的诊断产品组合，但它也大幅增加了公司的净债务负担。关于整合过程、潜在的监管延误或预计的成本协同是否会完全实现的担忧可能正在影响投资者情绪。</p>
</div><p>Furthermore, Danaher's full-year 2026 guidance, provided in late January, was characterized by some analysts as conservative. The company projected non-GAAP core revenue growth in the 3% to 6% range and adjusted diluted earnings per share between $8.35 and $8.50. While institutional investors have shown mixed activity, with some increasing their holdings in recent periods, the perceived tightness in valuation combined with this guidance might be leading some market participants to re-assess their positions. Analyst sentiment, while generally positive with a &#34;Moderate Buy&#34; consensus, includes previous downgrades that cited premium valuation and concerns about growth trajectory compared to historical levels, particularly regarding recovery in China and sustained diagnostic growth.</p>
<div class="lb-trans"><p>此外，丹纳赫在 1 月底提供的 2026 年全年指导被一些分析师视为保守。公司预计非 GAAP 核心收入增长在 3% 到 6% 之间，调整后的稀释每股收益在 8.35 美元到 8.50 美元之间。尽管机构投资者的活动表现不一，有些在近期增加了持股，但由于估值的紧张感与此指导相结合，可能导致一些市场参与者重新评估他们的持仓。分析师情绪总体上是积极的，达成了 “适度买入” 的共识，但包括之前的下调，指出了溢价估值和对增长轨迹的担忧，特别是关于中国的复苏和持续的诊断增长。</p>
</div><h2>Technical Analysis of Danaher Corp (DHR)</h2>
<div class="lb-trans"><h2>丹纳赫公司 (DHR) 的技术分析</h2>
</div><p>Technically, Danaher Corp (DHR) shows a MACD (12,26,9) value of [-5.82], indicating a sell signal. The RSI at 29.09 suggests sell condition and the Williams %R at -90.95 suggests oversold condition. Please monitor closely.</p>
<div class="lb-trans"><p>从技术上看，丹纳赫公司 (DHR) 的 MACD (12,26,9) 值为 [-5.82]，显示出卖出信号。RSI 为 29.09，表明卖出状态，Williams %R 为 -90.95，表明超卖状态。请密切关注。</p>
</div><h2>Fundamental Analysis of Danaher Corp (DHR)</h2>
<div class="lb-trans"><h2>丹纳赫公司 (DHR) 的基本面分析</h2>
</div><p>Danaher Corp (DHR) is in the Healthcare Services &amp; Equipment industry. Its latest annual revenue is $24.57B, ranking 7 in the industry. The net profit is $3.61B, ranking 4 in the industry. Company Profile</p>
<div class="lb-trans"><p>丹纳赫公司 (DHR) 处于医疗服务与设备行业。其最新年收入为 245.7 亿美元，在行业中排名第 7。净利润为 36.1 亿美元，在行业中排名第 4。公司简介</p>
</div><p>Over the past month, multiple analysts have rated the company as Buy, with an average price target of $263.31, a high of $310.00, and a low of $220.00.</p>
<div class="lb-trans"><p>在过去一个月中，多位分析师将该公司评级为买入，平均目标价为 263.31 美元，最高价为 310.00 美元，最低价为 220.00 美元。</p>
</div><h2>More details about Danaher Corp (DHR)</h2>
<div class="lb-trans"><h2>关于丹纳赫公司 (DHR) 的更多细节</h2>
</div><p>Company Specific Risks:</p>
<div class="lb-trans"><p>公司特定风险：</p>
</div><ul>
<li>Elevated financial leverage has resulted from the recent $9.9 billion premium-priced acquisition of Masimo Corporation, increasing Danaher's debt-to-equity ratio to approximately 3.2x.</li>
<li>Market skepticism persists regarding the value creation potential of the Masimo acquisition, coupled with concerns about Danaher's perceived loss of momentum and lagging share performance in recent years.</li>
<li>Danaher faces an intensifying competitive landscape in its key market segments, as evidenced by recent strong performance and raised revenue guidance from a major competitor, Agilent Technologies.</li>
</ul>
<div class="lb-trans"><ul>
<li>最近以 99 亿美元的溢价收购麦斯莫医疗导致财务杠杆上升，使丹纳赫的债务与股本比率增加至约 3.2 倍。</li>
<li>市场对麦斯莫收购的价值创造潜力持怀疑态度，同时对丹纳赫在最近几年表现滞后和失去动力的担忧依然存在。</li>
<li>丹纳赫在其关键市场领域面临日益激烈的竞争环境，最近主要竞争对手安捷伦科技 (Agilent Technologies) 的强劲表现和提高的收入指导便是明证。</li>
</ul>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div>

丹纳赫公司股票（DHR）在 3 月 12 日下跌了 3.55%：下跌背后的原因